Recent Updates
Recently added Catalysts
GKOS Positive Sentiment

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

Wednesday, September 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Glaukos Corporation has launched the 'Could it be KC?' campaign to raise awareness about keratoconus, a rare eye condition. The initiative, which features NBA Champion Stephen Curry, aims to improve recognition and early detection of the disease. The campaign will expand its activities further in 2027 to continue its educational efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Partnership with NBA Champion Stephen Curry enhances campaign visibility.
  • Focus on raising awareness for keratoconus can lead to earlier detection.
  • Educational efforts may improve patient outcomes in the long run.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
8.7%
average across 4 past catalysts
Lead asset
Gen 2 Travoprost Intracameral
Phase 3 · Glaucoma

Full Press Release Details

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening c

Frequently Asked Questions

What is the 'Could it be KC?' campaign?

It's a campaign launched by Glaukos to raise awareness about keratoconus.

Who is partnering with Glaukos for this campaign?

NBA Champion Stephen Curry is partnering with Glaukos for the campaign.

What is keratoconus?

Keratoconus is a rare, progressive eye condition that threatens sight.

When will the campaign expand its activities?

The campaign plans to expand its activities in 2027.

ShareAdd on Google
Tags: GKOS Viatris Investor Conferences Healthcare Glaukos Stephen Curry keratoconus eye health ophthalmic technology
Last updated: Sep 23, 2026

Biotech snapshot

Cash runway
$286M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Gen 2 Travoprost IntracameralPhase 3
Glaucoma →

Catalyst track record

+66%
best trade around GKOS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GKOS.

See every catalyst's timing & PoA →